Obesity compounds closest to market focus on more traditional CNS targets to control appetite. For example, Belviq lorcaserin from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) and Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), which FDA approved last month, is a serotonin 5-HT2C receptor agonist; and Qnexa phentermine/topiramate from Vivus Inc. (NASDAQ:VVUS), which has a July 17 PDUFA date, is a combination of two already approved centrally acting drugs. Companies contacted by BioCentury believe the next generation of programs in